<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="2682">
  <stage>Registered</stage>
  <submitdate>11/11/2009</submitdate>
  <approvaldate>11/11/2009</approvaldate>
  <nctid>NCT01076491</nctid>
  <trial_identification>
    <studytitle>High Dose Inhaled Mannitol Study</studytitle>
    <scientifictitle>A Pilot Study to Investigate the Feasibility and Tolerability of Inhaling a High Dose of Dry Powder Mannitol (IDPM) Per Breath Administered Via a Dry Powder Inhaler Loaded With a Single Capsule in Subjects With Bronchiectasis</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>DPM-DEV-102b</secondaryid>
    <secondaryid>DPM-DEV-102b</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Bronchiectasis</healthcondition>
    <conditioncode>
      <conditioncode1>Respiratory</conditioncode1>
      <conditioncode2>Other respiratory disorders / diseases</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - mannitol

Treatment: drugs: mannitol
inhaled mannitol - single doses of either 70 mg or 90 mg

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>emitted dose</outcome>
      <timepoint>single measure</timepoint>
    </primaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  adult subjects with non-CF bronchiectasis

          -  FEV1 &gt; 50 % predicted and &gt; 1.0L</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  bronchiectasis due to CF or endobronchial lesion

          -  respiratory infection requiring IV antibiotics in last 4 weeks

          -  pregnancy

          -  significant haemoptysis in last 6 months

          -  active TB

          -  end stage ILD

          -  contraindications as determined by investigator</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose />
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1/Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>1/01/2009</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>10</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/04/2009</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW</recruitmentstate>
    <hospital>Royal Prince Alfred Hospital - Sydney</hospital>
    <postcode>2050 - Sydney</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Pharmaxis</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>This study is to investigate the safety and tolerability of high doses of inhaled mannitol in
      subjects with bronchiectasis to further direct development of an improved drug delivery
      system.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT01076491</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>